| ReMIND – Discovery Stage ReMIND | Jonathan Sebat | Modeling the genetic basis of psychopathology in schizophrenia and autism |
$12,703,708 |
| Manufacturing Network Grant | Dan S Kaufman | UCSD Advanced Cell Therapy Laboratory |
$2,000,000 |
| Foundation – Discovery Stage Research Projects | Dr Marianna Alperin | Harnessing the rejuvenating capacity of pregnancy-associated factors to restore aged stem cell function |
$1,539,520 |
| Foundation – Discovery Stage Research Projects | Dr. Alon Goren | Establishment of a novel approach to systematically study the dynamic organization of protein complexes in stem cells |
$1,515,601 |
| Foundation – Discovery Stage Research Projects | Heidi Cook-Andersen | Towards a trophectoderm stem-cell model representing human blastocysts of the highest implantation potential |
$1,584,000 |
| Foundation – Discovery Stage Research Projects | Dr. Alexis Komor | Development of a stem-cell based approach to interpret global effects of genetic variants contributing to neurodevelopmental disease risk |
$1,518,982 |
| Foundation – Discovery Stage Research Projects | Francesca Soncin | Drivers of trophoblast stem/progenitor cell identity in human placenta |
$993,881 |
| Discovery Research Projects | Dr. Steven F Dowdy | Development of Anti-COVID RNAi Therapeutics Using Human iPSC-Derived Alveolar Epithelial Cells |
$150,000 |
| Discovery Research Projects | Dr Karen Christman | Pro-healing biomaterial for treating lung inflammation associated with COVID-19 |
$221,758 |
| Alpha Stem Cell Clinics Network Expansion | Catriona Jamieson | UC San Diego Health CIRM Alpha Stem Cell Clinic |
$8,000,000 |
| Conference – The 2016 Alpha Stem Cell Clinic Annual Symposium | Catriona Jamieson | UCSD Division of Regenerative Medicine and CIRM Alpha Clinics Network Symposium |
$37,778 |
| Quest – Discovery Stage Research Projects | Dr. Neil Carson Chi | Modulating cardiac myosin heavy chain isoform expression for treating cardiomyopathies |
$2,772,000 |
| Quest – Discovery Stage Research Projects | Professor Alysson R Muotri | A treatment for Rett syndrome using glial-restricted neural progenitor cells |
$1,402,240 |
| Quest – Discovery Stage Research Projects | Dr. Joseph G. Gleeson | Novel antisense therapy to treat genetic forms of neurodevelopmental disease. |
$1,180,654 |
| Quest – Discovery Stage Research Projects | Dr. Michael Karin | Targeting pancreatic cancer stem cells with DDR1 antibodies. |
$1,425,600 |
| Quest – Discovery Stage Research Projects | Gene Wei-Ming Yeo | RNA-directed therapy for Huntington’s disease |
$1,253,110 |
| Quest – Discovery Stage Research Projects | Ziwei Huang | Development of a new therapeutic for directing target specific stem cell migration and treatment |
$1,129,512 |
| Quest – Discovery Stage Research Projects | Dan S Kaufman | Human iPSC-derived chimeric antigen receptor expressing macrophages for improved cancer treatment. |
$1,256,332 |
| Quest – Discovery Stage Research Projects | Dr. Tannishtha Reya | Targeting Critical Regulators of Cancer Stem Cells |
$1,148,264 |
| Quest – Discovery Stage Research Projects | Tariq M Rana | Development of COVID-19 Antiviral Therapy Using Human iPSC-Derived Lung Organoids |
$250,000 |
| Quest – Discovery Stage Research Projects | Dan S Kaufman | Human iPSC-derived chimeric antigen receptor-expressing macrophages for cancer treatment |
$222,200 |
| Quest – Discovery Stage Research Projects | Prof James S Hagood | Mesenchymal stem cell extracellular vesicles as therapy for pulmonary fibrosis |
$0 |
| Quest – Discovery Stage Research Projects | Dr. Eric D. Adler MD | Genetically Modified Hematopoietic Stem Cells for the Treatment of Danon Disease |
$1,393,200 |
| Quest – Discovery Stage Research Projects | Dr. Jonathan H Lin | Small Molecule Proteostasis Regulators to Treat Photoreceptor Diseases |
$1,153,937 |
| Quest – Discovery Stage Research Projects | Dr. Tannishtha Reya | Targeting Cancer Stem Cells in Hematologic Malignancies |
$1,960,560 |
| Quest – Discovery Stage Research Projects | Mark H Tuszynski | Neural Stem Cell Relays for Severe Spinal Cord Injury |
$1,638,900 |
| Quest – Discovery Stage Research Projects | Dr Yang Xu | Development of immune invisible beta cells as a cell therapy for type 1 diabetes through genetic modification of hESCs |
$1,924,791 |
| Quest – Discovery Stage Research Projects | Professor Yuan Chen | A Novel Approach to Eradicate Cancer Stem Cells |
$279,977 |
| Quest – Discovery Stage Research Projects | Professor Alysson R Muotri | A treatment for Zika virus infection and neuroprotection efficacy |
$1,924,524 |
| Quest – Discovery Stage Research Projects | Dan S Kaufman | Targeted off-the-shelf immunotherapy to treat refractory cancers |
$1,936,936 |
| Inception – Discovery Stage Research Projects | Karl Karl J. Wahlin | An IPSC cell based model of macular degeneration for drug discovery. |
$232,200 |
| Inception – Discovery Stage Research Projects | Gerald P Morris | Identification of antigenic neo-epitopes from in vitro reprogrammed human tissue precursors for regenerative therapy |
$193,500 |
| Inception – Discovery Stage Research Projects | Dr. Tannishtha Reya | Reprogramming human stem cells for blood cell generation |
$210,060 |
| Inception – Discovery Stage Research Projects | Professor Alysson R Muotri | Reverse transcriptase inhibitors as a novel therapeutic approach for neurological autoimmune disorders |
$210,060 |
| Inception – Discovery Stage Research Projects | Dionicio Siegel | New Methods for the Chemical Expansion of Hematopoietic Stem and Progenitor Cells |
$232,200 |
| Inception – Discovery Stage Research Projects | Karl Karl J. Wahlin | Microenvironment based optimization of retinal induction using CRISPR-CAS9 reporter pluripotent stem cells as an expandable source of retinal progenitors and photoreceptors. |
$232,200 |
| Therapeutic Translational Research Projects | Dr Karen Christman | Pro-regenerative infusible ECM biomaterial for treating acute myocardial infarction |
$4,353,438 |
| Therapeutic Translational Research Projects | Dr. Eric D. Adler MD | Ex Vivo Modified Hematopoietic Stem Cells to Treat Danon Disease |
$5,180,389 |
| Therapeutic Translational Research Projects | Stephanie Cherqui | CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$4,846,579 |
| Therapeutic Translational Research Projects | Mark H Tuszynski | Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,235,897 |
| Therapeutic Translational Research Projects | Dan S Kaufman | Human Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment |
$3,260,000 |
| Therapeutic Translational Research Projects | Catriona Jamieson | A Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia |
$2,511,767 |
| Therapeutic Translational Research Projects | Ezra Cohen | Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies |
$5,795,584 |
| Therapeutic Translational Research Projects | Dr Karen Christman | Injectable pro-regenerative scaffold for treating symptomatic peripheral artery disease |
$2,839,317 |
| Therapeutic Translational Research Projects | Dr. Lawrence S. B. Goldstein | Human Embryonic Stem Cell-Derived Neural Stem Cell Transplants in Amyotrophic Lateral Sclerosis |
$1,790,000 |
| SPARK | James Murphy | Summer Program To Accelerate Regenerative Medicine Knowledge (SPARK) |
$488,621 |
| Conference II | Dr. Stephanie Cherqui | Gene Therapy Initiative 1st Annual Symposium |
$27,500 |
| Conference II | Dr. Adam Engler | BIC 2024 – 24th Annual UC Systemwide Symposium on Bioengineering at UC San Diego |
$50,000 |
| Conference II | Dr. Robert Lie-Yuan Sah | 2016 Tissue Engineering and Regenerative Medicine International Society – Americas (TERMIS-AM) Conference in San Diego, CA on December 11-14, 2016 |
$40,000 |
| Conference II | Prof. John M. Ravits | California ALS Research Summit 2016 |
$11,400 |
| Clinical Trial Stage Projects | Prof. Olivia Kim-McManus | Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A |
$960,713 |
| Clinical Trial Stage Projects | Dr. Stephanie Cherqui | Phase 1/2 study for autologous human CD34+ hematopoietic stem cells ex vivo transduced with pCCL-CTNS lentiviral vector for treatment of Cystinosis. |
$11,999,944 |
| Clinical Trial Stage Projects | Thomas J Kipps | A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers |
$18,292,674 |
| Late Stage Preclinical Projects | Mark H Tuszynski | Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,000,000 |
| Late Stage Preclinical Projects | Thomas J Kipps | Late Stage Pre-Clinical Development of a Cirmtuzumab Based CAR T-cell for the Treatment of ROR1+ Hematological Malignancies |
$1,630,360 |
| Late Stage Preclinical Projects | Dr. Stephanie Cherqui | Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis |
$5,273,189 |
| Alpha Stem Cell Clinics | Catriona Jamieson | Alpha Stem Cell Clinic for the Development of Regenerative Therapies |
$8,679,137 |
| Tools and Technologies III | Dr. Shyni Varghese | Technologies to improve in vivo function of transplanted stem cells |
$1,373,683 |
| Tools and Technologies III | Shaochen Chen | Development of 3D Bioprinting Techniques using Human Embryonic Stem Cells Derived Cardiomyocytes for Cardiac Tissue Engineering |
$1,368,264 |
| Conference | Shu Chien | 10th Annual UC Systemwide Bioengineering Symposium |
$8,000 |
| Conference | Shu Chien | The 14th UC Systemwide Bioengineering Symposium |
$5,000 |
| Conference | Prof. John M. Ravits | Cell Therapy for amyotrophic Lateral Sclerosis (ALS) -Testing the Limits: What should we use as preclinical standards of clinical trials? |
$7,193 |
| Conference | Dong-Er Zhang | International RUNX Workshop |
$24,000 |
| Conference | Dr. Lawrence S. B. Goldstein | San Diego Stem Cell Science Education Symposium at UCSD |
$6,237 |
| Conference | Dr. Joan Heller Brown | International Society for Heart Research (ISHR) XX1 World Congress |
$10,000 |
| Disease Team Planning | Dr. Dennis Carson | CIRM Planning Grant in Leukemia |
$52,174 |
| Disease Team Planning | Lawrence Goldstein | Human Stem Cell Approaches to Alzheimers Disease Therapies |
$55,000 |
| Basic Biology V | Dr. Dianne McKay | Role of intracytoplasmic pattern recognition receptors in HSC engraftment |
$615,639 |
| Basic Biology V | Christian Metallo | Metabolic regulation of cardiac differentiation and maturation |
$1,124,834 |
| Basic Biology V | Maike Sander | Defining links between chromatin state and developmental competence |
$1,050,300 |
| Basic Biology V | Miles F Wilkinson | New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors |
$552,811 |
| Basic Biology V | Dr. Cornelis Murre | Epigenetic mechanisms that enforce pluripotency in embryonic stem cells |
$1,160,997 |
| Basic Biology V | Dr. Wei Wang | Systems-level discovery of the regulatory mechanisms directing differentiation of hESC |
$1,161,000 |
| Basic Biology V | Dr. Lawrence S. B. Goldstein | Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes |
$1,050,300 |
| Basic Biology V | Dr. David A. Cheresh | CD61-driven stemness program in epithelial cancer |
$1,161,000 |
| Disease Team Therapy Development III | Thomas J Kipps | Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) |
$4,179,598 |
| Patent Assistance Fund Awards | Dr. Rubén D. Flores | Patent Assistance Fund Application – UCSD |
$38,162 |
| Early Translational from Disease Team Conversion | Dr. Lawrence S. B. Goldstein | Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$4,139,754 |
| Early Translational IV | Professor Alysson R Muotri | A drug-screening platform for autism spectrum disorders using human astrocytes |
$1,656,456 |
| Tissue Collection for Disease Modeling | Dr. Joseph G. Gleeson | CIRM Tissue Collection for Neurodevelopmental Disabilities |
$830,426 |
| Tissue Collection for Disease Modeling | Dr. Kang Zhang M.D. | Generation of fibroblast cell lines in patients with common blinding eye diseases |
$1,034,425 |
| Tissue Collection for Disease Modeling | Dr. James Brewer | Collection of skin biopsies to prepare fibroblasts from patients with Alzheimer’s disease and cognitively healthy elderly controls |
$643,693 |
| New Faculty Physician Scientist | Dr. Mana M Parast | Human pluripotent stem cell-based therapeutics for preeclampsia |
$2,974,750 |
| Basic Biology IV | George Sen | Regulation of Epidermal Self-Renewal and Differentiation by Histone and DNA Demethylases. |
$1,080,000 |
| Basic Biology IV | Miles F Wilkinson | Role of the NMD RNA Decay Pathway in Maintaining the Stem-Like State |
$1,360,450 |
| Basic Biology IV | Ananda Goldrath | Mechanisms to protect hESC-derived cells from allogenic immune rejection |
$1,160,997 |
| Basic Biology IV | Maike Sander | Deciphering transcriptional control of pancreatic beta-cell maturation in vitro |
$1,258,560 |
| Basic Biology IV | Dr. David Traver | DECIPHERING THE INSTRUCTIONS FOR VERTEBRATE HSC SPECIFICATION AND AMPLIFICATION. |
$1,363,698 |
| Basic Biology IV | Gene Wei-Ming Yeo | Stem cell models to analyze the role of mutated C9ORF72 in neurodegeneration |
$1,260,360 |
| Early Translational III | Dr. Lawrence S. B. Goldstein | Identifying Drugs for Alzheimer’s Disease with Human Neurons Made From Human IPS cells |
$1,774,420 |
| Early Translational III | Dr. Yang Xu | Human ES cell based therapy of heart failure without allogenic immune rejection |
$1,857,600 |
| Early Translational III | Dr. Eric D. Adler MD | Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease |
$1,701,575 |
| Early Translational III | Mark H Tuszynski | Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury |
$4,600,447 |
| Early Translational III | Gene Wei-Ming Yeo | Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons |
$1,532,323 |
| Training Grant I-1 | Dr. Lawrence S. B. Goldstein | Interdisciplinary Stem Cell Training Program at UCSD |
$3,459,396 |
| Research Training II | Dr Sylvia Evans | Interdisciplinary Stem Cell Training Program at UCSD II |
$7,432,600 |
| Basic Biology III | Dr. Deborah H Spector Dr. | Viral-host interactions affecting neural differentiation of human progenitors |
$1,372,660 |
| Basic Biology III | Dr. David A. Cheresh | Molecular basis of human ES cell neurovascular differentiation and co-patterning |
$1,359,996 |
| Basic Biology III | Dr. Anirvan Ghosh Dr. | Investigation of synaptic defects in autism using patient-derived induced pluripotent stem cells |
$843,597 |
| Basic Biology III | Dr. Kun Zhang | Functional characterization of mutational load in nuclear reprogramming and differentiation |
$1,295,318 |
| Basic Biology III | Gene Wei-Ming Yeo | Neural and general splicing factors control self-renewal, neural survival and differentiation |
$1,287,619 |
| Basic Biology III | Dr. Benhai Zheng Dr. | Generation and characterization of corticospinal neurons from human embryonic stem cells |
$1,355,063 |
| Basic Biology III | Dr. Farah Sheikh Dr. | Molecular Mechanisms Underlying Human Cardiac Cell Junction Maturation and Disease Using Human iPSC |
$1,341,955 |
| Basic Biology III | Dr. Charles C. King Dr. | Biological relevance of microRNAs in hESC differentiation to endocrine pancreas |
$1,313,649 |
| Tools and Technologies II | Karl H. Willert | Homologous recombination in human pluripotent stem cells using adeno-associated virus. |
$1,659,043 |
| Tools and Technologies II | Dr. Lawrence S. B. Goldstein | Developing a method for rapid identification of high-quality disease specific hIPSC lines |
$1,686,069 |
| Tools and Technologies II | Shu Chien | Development of Synthetic Microenvironments for Stem Cell Growth and Differentiation |
$1,706,628 |
| Early Translational II | Professor Alysson R Muotri | Developing a drug-screening system for Autism Spectrum Disorders using human neurons |
$1,376,198 |
| Early Translational II | Catriona Jamieson | Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,103,041 |
| Research Leadership | Dr. Eric T. Ahrens | Molecular Imaging for Stem Cell Science and Clinical Application |
$5,680,474 |
| New Faculty I | Dr. David Traver | Genetic dissection of mesodermal commitment to the hematopoietic fates. |
$2,150,620 |
| Early Translational I | Dr. Yang Xu | Developing induced pluripotent stem cells into human therapeutics and disease models |
$5,165,028 |
| Transplantation Immunology | Prof. Martin Marsala | Induction of immune tolerance after spinal grafting of human ES-derived neural precursors |
$1,387,800 |
| Transplantation Immunology | Dr. Yang Xu | Induction of immune tolerance to human embryonic stem cell-derived allografts |
$1,192,680 |
| Tools and Technologies I | Dr. Ying Liu | Generation of disease models for neurodegenerative disorders in hESCs by gene targeting |
$709,829 |
| Tools and Technologies I | Dr. Steven F Dowdy | TAT Cell-Permeable Protein Delivery of siRNAs for Epigenetic Programming of Human Pluripotent and Adult Stem Cells |
$720,000 |
| Shared Labs | Karl H. Willert | Enhancing Facilities for Genetic Manipulation and Engineering of Human Embryonic Stem Cells at UCSD |
$1,728,080 |
| Shared Labs | Karl H. Willert | Enhancing Facilities for Genetic Manipulation and Engineering of Human Embryonic Stem Cells at UCSD |
$1,737,133 |
| New Faculty II | Dr. Benjamin D. Yu | Regulation of Adult Stem Cell Proliferation by RAS and Cell-Permeable Proteins |
$3,017,978 |
| New Faculty II | Dr. Shyni Varghese | A Novel Microenvironment-Mediated Functional Skeletal Muscle from Human Embryonic Stem Cells and their In Vivo Engraftment |
$2,300,569 |
| New Faculty II | Dr. Mana M Parast | Molecular Mechanisms of Trophoblast Stem Cell Specification and Self-Renewal |
$3,077,918 |
| New Faculty II | Catriona Jamieson | Derivation and Characterization of Myeloproliferative Disorder Stem Cells from Human ES Cells |
$3,065,572 |
| New Cell Lines | Dr. Steven F Dowdy | Protein transduction of transcription factors: a non-genetic approach to generate new pluripotent cell lines from human skin. |
$1,073,585 |
| Comprehensive Grant | Dr. Yang Xu | Mechanisms to maintain the self-renewal and genetic stability of human embryonic stem cells |
$2,467,200 |
| Comprehensive Grant | Prof. Martin Marsala | Spinal ischemic paraplegia: modulation by human embryonic stem cell implant. |
$2,356,090 |
| Comprehensive Grant | Dr. Lawrence S. B. Goldstein | Using Human Embryonic Stem Cells to Understand and to Develop New Therapies for Alzheimer’s Disease |
$1,859,414 |
| SEED Grant | Dr. Benhai Zheng Dr. | Genetic manipulation of human embryonic stem cells and its application in studying CNS development and repair |
$600,441 |
| SEED Grant | Dr. Anirvan Ghosh Dr. | Generation of forebrain neurons from human embryonic stem cells |
$587,591 |
| SEED Grant | Shu Chien | Combinatorial Platform for Optimizing Microenvironments to Control hESC Fate |
$577,148 |
| SEED Grant | Dr. Cornelis Murre | Generation of long-term cultures of human hematopoietic multipotent progenitors from embryonic stem cells |
$473,952 |
| SEED Grant | Catriona Jamieson | Derivation and Characterization of Cancer Stem Cells from Human ES Cells |
$616,305 |
| SEED Grant | Dr Sylvia Evans | Specification of Ventricular Myocyte and Pacemaker Lineages Utilizing Human Embryonic Stem Cells |
$585,600 |
| Basic Biology II | Dong-Er Zhang | RUNX1 in maintenance, expansion, and differentiation of therapeutic pluripotent stem cells |
$1,371,540 |
| Basic Biology II | Dr. Kun-Liang Guan | The function of YAP in human embryonic stem cells |
$1,245,693 |
| Disease Team Research I | Dr. Lawrence S. B. Goldstein | Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$5,694,308 |
| Disease Team Research I | Dr. Dennis A Carson | Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
| Basic Biology I | Gene Wei-Ming Yeo | RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,308,901 |
| Basic Biology I | Karl H. Willert | WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,329,298 |
| Research Training Grant | Professor Alysson R Muotri | Interdisciplinary Stem Cell Training Grant at UCSD III |
$5,366,188 |
| Progression Award – Discovery Stage Research Projects | Armin Blesch | Simplification of Excipient Solution for Implanting Candidate Human H9-scNSC Cell Line for Spinal Cord Injury |
$180,000 |
